pharmaphorum Podcast

Collaborative perseverance to bring change to medicine access

Recently, pharmaphorum web editor Nicole Raleigh spoke with Herbert Altmann, head of commercialisation and access solutions Europe at PharmaLex, and Casper Paardekooper, partner at Vintura. AmerisourceBergen completed the acquisition of PharmaLex (and Vintura, which was owned by PharmaLex).

Botanicals in pharma: Potential and pitfalls

In today’s podcast, Saad Harti, founder and CEO of Legacy Healthcare, joins Editor in Chief Jonah Comstock to discuss this exciting old, yet new category.  

Clinical trial diversity: An update

Editor in Chief Jonah Comstock welcomes back returning guest Dr. Jennifer Jones-McMeans, divisional vice president for global affairs for Abbot’s vascular business. Jennifer was on the podcast just over a year ago to talk about the importance of clinical trial diversity, and she’s back with an update on that important topic, as well as some news from Abbott in that area.

Changing personnel dynamics in the pharma world

In this episode of the pharmaphorum podcast, brought to you by Advanced Clinical, Advanced Clinical’s SVP Strategic Resourcing Steve Mattas and VP of Global Talent and Client Delivery James Nyssen speak with host Jonah Comstock about findings from a recent report by their company on the current personnel dynamics in pharma.

Retaining the human quality of healthcare in DTx

As DTx Europe came to a close at the British Medical Association in London, pharmaphorum web editor Nicole Raleigh spoke with Digital Medicine Society (DiMe) program lead, Alex Despotovic, discussing adoption of digital therapeutics and digital technologies in general in clinical practice, and the impact of the event itself overall.

Focusing on predictability and execution in digital trials

Recently attending the Veeva R&D and Quality Summit in Madrid, pharmaphorum web editor Nicole Raleigh sat down with Veeva’s president of Europe, Chris Moore. The event seen as a chance to bring the whole industry together, Moore explained how there is an excitement in the industry currently, with more drugs being developed, more conditions being treated – including those not before addressed – and that Veeva is endeavouring to do what it can to help raise the industry capabilities. So it is that the event has become a test bed to see whether the company is on the right track.

Genetic testing update with 23andMe’s Noura Abul-Husn

In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock is joined by Dr Noura Abul-Husn, VP of genomic health at 23andMe. 

Headlines and hot topics from ASCO and BIO

This week, pharmaphorum editor-in-chief Jonah Comstock headed to not one but two back-to-back events in the US. Starting with the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago, before hitting the floor at the BIO International Convention in Boston, there was plenty of innovation, news, and expert knowledge on display.
Fresh from the floor of BIO International, Jonah sat down with pharmaphorum Deep Dive editor Eloise McLennan to reflect on the biggest topics and trends from each event – and the impact these developments may have on pharma over the coming months.

The precision element at the heart of digital transformation

On the final day of Reuters Pharma Barcelona back in March, web editor Nicole Raleigh sat down with Graphite Digital’s CEO, Rob Verheul. The company – which has been working in the industry for 13 years now – has most recently been focusing on HCP engagement at a global scale, through use of digital channels.

AI in drug development: A reality check

In this episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock catches up with Adityo Prakash, CEO of Verseon, to shed some light on what the potential of AI in drug discovery really is.